This version of CRISPR uses an engineered protein called dCas9, together with an RNA molecule that acts as a mailing address for a particular site in the genome. This enables the dCas9-RNA complex ...

For CRISPR-based epigenetic editing, dCas9-DNMT3A plasmid and sgRNA were first mixed in 1:2 ratio, then mixed with 3.75 μl Lipofectamine 3000 reagent and 5 μl P3000 reagent in each well. Cells were ...

CRISPR screen was applied to the HCT116-dCas9-KRAB-MeCP2 cells for NGS. Anticancer potentials of silenced VELs were evaluated by in vitro assays (i.e MTT assay, apoptosis, cell cycle assay, 3D ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

Cell and gene therapy start-up NKure Therapeutics and international gene-editing company CRISPR Therapeutics have entered into a partnership to co-develop and co-commercialise CTX112 — a next ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces ...